Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
Go back to Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema| (NASDAQ: NTLA) | Delayed: 15.75 +0.08 (0.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.67 | 52 Week High | $30.40 | |||
| Open | $15.87 | 52 Week Low | $11.86 | |||
| Day High | $16.32 | P/E | N/A | |||
| Day Low | $15.57 | EPS | $0.00 | |||
| Volume | 5,103,380 | |||||
